Parkinson DiseaseNCT07488351
"Self-Compassion and Self-Efficacy in Parkinson's Disease: Associations With Symptoms, Function, and Quality of Life"
An observational study of Parkinson Disease and Physical Disability, run by Acibadem University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to evaluate the associations of self-compassion and self-efficacy levels with symptom severity, functional status, and quality of life in individuals with Parkinson's disease. Read more about this study
- Who is it for?
- Ages 40 to 85 years
- Conditions the study is for
- Parkinson Disease, Physical Disability
- What is being tested?
- Self-Report Questionnaire Assessment
- How many people
- 100 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 30 Mar 2026to 30 Mar 2027
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will consist of individuals diagnosed with Parkinson's disease who are classified as Hoehn and Yahr stage 1-3, aged between 40 and 85 years, and have sufficient cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department
Who may be able to join
- Clinical diagnosis of Parkinson's disease
- Hoehn and Yahr stage 1-3
- Age 40 to 85 years
- Mini-Mental State Examination (MMSE) score ≥24
- Sufficient cognitive function to communicate and complete study assessments
- Attending the Movement Disorders Outpatient Clinic, Department of Neurology
- Able and willing to provide written informed consent
Who cannot join
- Major depressive disorder or psychotic disorder
- Advanced dementia
- Uncontrolled chronic systemic disease (e.g., diabetes mellitus or hypertension)
- Severe cardiovascular or respiratory disease
- Additional neurological or orthopedic conditions that may affect assessment performance
- Severe visual or hearing impairment that could interfere with study assessments
- Inability to cooperate with the physiotherapist during study assessments
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Acibadem University
Istanbul, Turkey, +90
Nuray ALACA, 05324251290, nuray.alaca@acibadem.edu.tr
About this study
Official title: "Associations of Self-Compassion and Self-Efficacy With Symptom Severity, Functional Status, and Quality of Life in Individuals With Parkinson's Disease: A Cross-Sectional Study"
The aim of this study is to evaluate the associations of self-compassion and self-efficacy levels with symptom severity, functional status, and quality of life in individuals with Parkinson's disease.
- Conditions
- Parkinson Disease, Physical Disability
- Being tested
- Self-Report Questionnaire Assessment
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Self-Report Questionnaire AssessmentOther
This study does not involve any therapeutic intervention. Participants will complete a set of self-report questionnaires assessing self-compassion, self-efficacy, symptom severity, functional status, and quality of life. Data will be collected in a single session for observational analysis.
What is being measured
The primary outcome is the main question the study is designed to answer.
Self-Compassion Scale (SCS) Total Score
Self-Compassion Scale (SCS) total score. The Self-Compassion Scale consists of 26 items scored on a 1- to 5-point Likert scale. Total scores range from 1 to 5 (calculated as the mean of all items), with higher scores indicating greater self-compassion (better outcome).
Measured: Baseline (at the time of questionnaire completion)
Self-Efficacy for Managing Chronic Disease 6-Item Scale Total Score
Self-Efficacy for Managing Chronic Disease 6-Item Scale total score. The scale consists of 6 items scored from 1 (not at all confident) to 10 (totally confident). The total score is calculated as the mean of the six items, ranging from 1 to 10, with higher scores indicating greater self-efficacy for managing chronic disease (better outcome).
Measured: Baseline (at the time of questionnaire completion)
Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
Unified Parkinson's Disease Rating Scale (UPDRS) total score. The total score ranges from 0 to 199, with higher scores indicating greater Parkinson's disease severity and worse clinical status (worse outcome).
Measured: Baseline (at the time of questionnaire completion)
Secondary outcomes (4)
Timed Up and Go (TUG) Test Completion Time in Seconds
Functional mobility will be measured using the Timed Up and Go (TUG) test. The time required to stand up from a chair, walk 3 meters, turn, return, and sit down will be recorded in seconds. Longer times indicate poorer functional mobility.
Measured: Baseline (at the time of questionnaire completion)
Six-Minute Walk Test (6MWT) Distance in Meters
Functional exercise capacity will be measured using the Six-Minute Walk Test (6MWT). The total distance walked in six minutes will be recorded in meters. Greater distances indicate better functional capacity.
Measured: Baseline (at the time of questionnaire completion)
Mini-Balance Evaluation Systems Test (Mini-BESTest) Total Score
Dynamic balance will be measured using the Mini-Balance Evaluation Systems Test (Mini-BESTest), a 14-item performance-based assessment. Total scores range from 0 to 28, with higher scores indicating better balance performance.
Measured: Baseline (at the time of questionnaire completion)
Parkinson's Disease Questionnaire-39 (PDQ-39) Total Score
Quality of life will be measured using the Parkinson's Disease Questionnaire-39 (PDQ-39), a validated disease-specific instrument. Total scores range from 0 to 100, with higher scores indicating poorer quality of life.
Measured: Baseline (at the time of questionnaire completion)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2026
- Study start30 Mar 2026
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by Acibadem UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Acibadem University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nuray Alaca, Acibadem University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07488351
- Sponsor's protocol ID
- 2026-03-130
- Status last verified
- Jul 2026
- First submitted
- 18 Mar 2026
- Last updated
- 15 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "Associations of Self-Compassion and Self-Efficacy With Symptom Severity, Functional Status, and Quality of Life in Individuals With Parkinson's Disease: A Cross-Sectional Study"
- ClinicalTrials.gov ID
- NCT07488351
- Acronym / sponsor ID
- 2026-03-130
- Conditions
- Parkinson Disease, Physical Disability
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Acibadem UniversityUniversity, hospital or other
- Study start
- 30 Mar 2026 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Mar 2027 (estimated)
- First posted
- 23 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the associations of self-compassion and self-efficacy levels with symptom severity, functional status, and quality of life in individuals with Parkinson's disease.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 40 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of individuals diagnosed with Parkinson's disease who are classified as Hoehn and Yahr stage 1-3, aged between 40 and 85 years, and have sufficient cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department
Key inclusion criteria (7 listed)
- Clinical diagnosis of Parkinson's disease
- Hoehn and Yahr stage 1-3
- Age 40 to 85 years
- Mini-Mental State Examination (MMSE) score ≥24
- Sufficient cognitive function to communicate and complete study assessments
Key exclusion criteria (7 listed)
- Major depressive disorder or psychotic disorder
- Advanced dementia
- Uncontrolled chronic systemic disease (e.g., diabetes mellitus or hypertension)
- Severe cardiovascular or respiratory disease
- Additional neurological or orthopedic conditions that may affect assessment performance
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Self-Report Questionnaire AssessmentThis study does not involve any therapeutic intervention. Participants will complete a set of self-report questionnaires assessing self-compassion, self-efficacy, symptom severity, functional status, and quality of life. Data will be collected in a single session for observational analysis. | Other | – |
Primary outcome
Self-Compassion Scale (SCS) Total Score
Time frame: Baseline (at the time of questionnaire completion)
Self-Compassion Scale (SCS) total score. The Self-Compassion Scale consists of 26 items scored on a 1- to 5-point Likert scale. Total scores range from 1 to 5 (calculated as the mean of all items), with higher scores indicating greater self-compassion (better outcome).
Self-Efficacy for Managing Chronic Disease 6-Item Scale Total Score
Time frame: Baseline (at the time of questionnaire completion)
Self-Efficacy for Managing Chronic Disease 6-Item Scale total score. The scale consists of 6 items scored from 1 (not at all confident) to 10 (totally confident). The total score is calculated as the mean of the six items, ranging from 1 to 10, with higher scores indicating greater self-efficacy for managing chronic disease (better outcome).
Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
Time frame: Baseline (at the time of questionnaire completion)
Unified Parkinson's Disease Rating Scale (UPDRS) total score. The total score ranges from 0 to 199, with higher scores indicating greater Parkinson's disease severity and worse clinical status (worse outcome).
4 secondary outcomes
Timed Up and Go (TUG) Test Completion Time in Seconds
Time frame: Baseline (at the time of questionnaire completion)
Six-Minute Walk Test (6MWT) Distance in Meters
Time frame: Baseline (at the time of questionnaire completion)
Mini-Balance Evaluation Systems Test (Mini-BESTest) Total Score
Time frame: Baseline (at the time of questionnaire completion)
Parkinson's Disease Questionnaire-39 (PDQ-39) Total Score
Time frame: Baseline (at the time of questionnaire completion)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease and Physical Disability, run by Acibadem University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nuray ALACA (05324251290, nuray.alaca@acibadem.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Self-Compassion Scale (SCS) Total Score (time frame: Baseline (at the time of questionnaire completion)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026.